SavedAdd your journal

Journals / Klimik Dergisi / 2016 / Cilt: 29 - Sayı: 3

Moxifloxacin-Induced Stevens-Johnson Syndrome: A Case Report

Moksifloksasin Tedavisi Sırasında Gelişen Stevens-Johnson Sendromu: Bir Olgu Sunumu

Özgür GÜNAL
Necla TÜLEK
Seyhan BEYHAN
Eda KÖKSAL
Pages
136–137
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, a case of Stevens-Johnson syndrome developing after the use of moxifloxacin is presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stevens-Johnson syndrome is generally self-limiting, vesiculobullous and an acute-onset disease in which at least two mucosal areas are affected in addition to skin lesions It results in mortality in 3-18% of severe cases.
📊
Key Findings & Data:In etiology, especially drugs, a variety of infectious agents, malignancy, and collagen vascular disease play a role.
💡
Conclusion & Impact:In this study, a case of Stevens-Johnson syndrome developing after the use of moxifloxacin is presented.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Stevens-Johnson syndrome is generally self-limiting, vesiculobullous and an acute-onset disease in which at least two mucosal areas are affected in addition to skin lesions It results in mortality in 3-18% of severe cases. In etiology, especially drugs, a variety of infectious agents, malignancy, and collagen vascular disease play a role. Although there is no specific treatment, removing the disease-causing agent and supportive treatment are the first treatment to be applied. Moxifloxacin is a frequently-preferred fourth generation quinolone in the treatment of pneumonia. In this study, a case of Stevens-Johnson syndrome developing after the use of moxifloxacin is presented.

Özet

Stevens-Johnson sendromu, akut başlangıçlı, genellikle kendini sınırlayan, vezikülobüllöz, deri lezyonlarının yanı sıra en az iki mukozal alanın tutulduğu bir hastalıktır. Ağır olguların %3-18'inde mortaliteyle sonuçlanmaktadır. Etyolojide özellikle ilaçlar, çeşitli infeksiyon ajanları, malignite ve kolajen doku hastalıkları rol oynamaktadır. Spesifik bir tedavisi olmamakla birlikte sebep olan ajandan uzaklaşılması ve destek tedavisi ilk olarak uygulanacak tedavi yöntemidir. Moksifloksasin pnömoni tedavisinde sıklıkla tercih edilen dördüncü kuşak bir kinolondur. Bu çalışmamızda alt solunum yolu infeksiyonu nedeniyle moksifloksasin kullanımını takiben gelişen Stevens-Johnson sendromlu olgu sunulmaktadır.

🔖

Cite This Article

GÜNAL, Ö., TÜLEK, N., BEYHAN, S., KÖKSAL, E. (2022). Moxifloxacin-Induced Stevens-Johnson Syndrome: A Case Report. Klimik Dergisi, Cilt: 29 - Sayı: 3, 136–137. https://ajindex.com/articles/573599

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Becker DS. Toxic epidermal necrolysis. Lancet. 1998; 351(9113): 1417-20. [CrossRef] Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001; 137(6): 765-70.
  2. Loboda J, Dudzik A, Chomyszyn-Gajewska M. Stevens-Johnson Syndrom and Toxic Epidermal Necrolysis--based on literature. Przegl Lek. 2015; 72(1): 35-7.
  3. Castana O, Rempelos G, Anagiotos G, Apostolopoulou C, Dimit- rouli A, Alexakis D. Stevens-Johnson syndrome: a case report. Ann Burns Fire Disasters. 2009; 22(3): 147-51.
  4. Hinc-Kasprzyk J, Polak-Krzeminska A, Ozóg-Zabolska I. Toxic epidermal necrolysis. Anaesthesiol Intensive Ther. 2015; 47(3): 257-62. [CrossRef] Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Derma- tol. 1990; 126(1): 43-7. [CrossRef] Nappe TM, Goren-Garcia SL, Jacoby JL. Stevens-Johnson syndrome after treatment with azithromycin: an uncommon culprit. Am J Emerg Med. 2016; 34(3): 676.e1-3. [CrossRef] Mavilia L, Trifirò C, Mercuri SR. Stevens-Johnson syndrome ca- used by cefepime? J Pharmacol Pharmacother. 2015; 6(1): 35-6. [CrossRef] Romano A, Caubet JC. Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis. J Allergy Clin Immunol Pract. 2014; 2(1): 3-12. [CrossRef] Lee GM, Kim K, Park JB, Suh J III. A case of Stevens-Johnson syndrome caused by moxifloxacin. Korean J Med. 2009; 77(5): 1124-7.
  5. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens- Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf. 2002; 25(13): 965-72. [CrossRef] Rappersberger K, Foedinger D. Treatment of erythema multifor- me, Stevens-Johnson syndrome, and toxic epidermal necroly- sis. Dermatol Therapy. 2002; 15(4): 397-408. [CrossRef] Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-John- son syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008; 40(2): 129-38. [CrossRef] Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. To- xic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000; 136(3): 323-7. [CrossRef] Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndro- me, toxic epidermal necrolysis and SJS-TEN overlap: a retros- pective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 200